SCHEMBL1980122

SCHEMBL1980122

CC(C)c1cccc(Oc2ccc(N[C@H](C)C(N)=O)cn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 6/20 0.45
FPR2 P25090 5/20 0.45
LTA4H P09960 1/20 0.44
SYK P43405 1/20 0.43
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
RAB9A P51151 1/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
CASP3 P42574 1/20 0.41
KMT2A Q03164 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NTRK1 P04629 1/20 0.40
RORC P51449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1981054 0.87 FPR2 (0.46) SCN9AFPR2LTA4HSYKACACB
SCHEMBL1982040 0.86 SYK (0.44) SCN9ASYKACACBMEN1KMT2A
SCHEMBL1980121 0.82 KMT2A (0.48) LTA4HACACBACACARAB9AGAA
SCHEMBL21980940 0.82 KMT2A (0.48) LTA4HACACBACACARAB9AGAA
SCHEMBL13832464 0.81 LTA4H (0.51) LTA4HRAB9AGAAMEN1CASP3
SCHEMBL1979061 0.79 SCN9A (0.41) SCN9AFPR2LTA4HSYKRAB9A
SCHEMBL21980932 0.78 LTA4H (0.48) LTA4HACACBACACARAB9AGAA
SCHEMBL13268415 0.78 LTA4H (0.48) LTA4HACACBACACARAB9AGAA
SCHEMBL13721111 0.78 SCN9A (0.46) SCN9AFPR2LTA4HSYKGAA
SCHEMBL1979735 0.76 KEAP1 (0.42) SCN9AFPR2LTA4HSYKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 88/4885FPR2 4838/4885LTA4H 4140/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 SCN9A 93/4885FPR2 4820/4885LTA4H 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.